Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088647 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating MST-997 in Advanced Malignant Solid Tumors
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00088647 is a Phase 1 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer.
The verdict
NCT00088647, a Phase 1 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in Intralipid 20% administered on a weekly schedule to subjects with advanced malignant solid tumors.
Interventions
- DRUG MST-997
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088647
The ClinicalTrials.gov registry entry for NCT00088647 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MST-997 is the first listed.
NCT00088647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088647 about?
NCT00088647 is a clinical study titled "Study Evaluating MST-997 in Advanced Malignant Solid Tumors". The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in Intralipid 20% administered on a weekly schedule to subjects with advanced malignant solid tumors.
What is the current status of trial NCT00088647?
This trial is currently terminated. It is a Phase 1 study.
What interventions are being tested in trial NCT00088647?
The interventions under investigation include: MST-997 (DRUG).
Who is sponsoring clinical trial NCT00088647?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.